What is JBIO's debt-to-equity?

JBIO (JBIO) reported debt-to-equity of 0× in Q1 2026.

What is the long-term trend for JBIO's debt-to-equity?

Over 3 years (2021 to 2025), JBIO's debt-to-equity has grown at a -7.6% compound annual growth rate (CAGR), from 0× to 0×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

JBIO JBIO Debt-to-equity

Debt-to-equity at other companies

Vertex PharmaceuticalsVRTX

0.1×0.0×

Travere Therapeutics, Inc.TVTX

0.2×-2.6×

Vera TherapeuticsVERA

0.2×0.0×

AnaptysBio, Inc.ANAB

0×-0.5×

Cullinan Therapeutics, Inc.CGEM

0×0.0×

Viridian Therapeutics, Inc.VRDN

0.1×0.0×

Other financials

Income statement

See full

Operating income-$43.4M-85.8%

Net income-$40.4M-5.8%

EPS (diluted)-$0.57+95.3%

Balance sheet

See full

Cash & equivalents$55.1M+24.6%

Total debt$808.0K+159%

Total equity$296.5M+455%

Total assets$319.4M+312%

Cash flow

See full

Operating cash flow-$24.1M-28.4%

CapEx$3.0K—

Free cash flow-$33.7M—

Valuation

See full

Market cap$1.33B—

Enterprise value$1.28B—

Returns & leverage

See full

Return on equity-132.5%+120pp

Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

total debt/total stockholders equity=0×

Based on the most recent quarter.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is JBIO's debt-to-equity?: JBIO (JBIO) reported debt-to-equity of 0× in Q1 2026.
What is the long-term trend for JBIO's debt-to-equity?: Over 3 years (2021 to 2025), JBIO's debt-to-equity has grown at a -7.6% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-equity mean?: Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.